Patricia L. Novak
Corporate Officer/Principal at University of California, Irvine
Profile
Patricia L.
Novak is Vice President of Program Development for Cardium Therapeutics, Inc., which she joined in November 2005.
She was Executive Director of Program Management and R&D for Metabasis Therapeutics and Vice President of Program Management for Collateral Therapeutics from 2000 to 2003 and Senior Director of Program Management from 1997 to 2000.
From 1991 to 1997, Dr. Novak was Director of Research and Development Planning and Project Management for Gensia, Inc. and Clinical Project Manager of Alpha Therapeutic Corporation from 1987 to 1991.
She received a PhD in Biological Sciences from the University of California, Irvine.
Patricia L. Novak active positions
| Companies | Position | Start |
|---|---|---|
| University of California, Irvine | Corporate Officer/Principal | - |
Former positions of Patricia L. Novak
| Companies | Position | End |
|---|---|---|
| Cardium Therapeutics, Inc. /Old/ | Corporate Officer/Principal | 2006-01-22 |
Collateral Therapeutics, Inc.
 Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Corporate Officer/Principal | 2002-12-31 |
SICOR, Inc.
 SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | Corporate Officer/Principal | 1996-12-31 |
Alpha Therapeutic Corp.
 Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA. | Corporate Officer/Principal | 1990-12-31 |
| GENE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Patricia L. Novak
| University of California, Irvine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GENE BIOTHERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
| Cardium Therapeutics, Inc. /Old/ | Commercial Services |
Alpha Therapeutic Corp.
Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA. | Health Technology |
Metabasis Therapeutics, Inc.
 Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Health Technology |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Commercial Services |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | Health Technology |
- Stock Market
- Insiders
- Patricia L. Novak